[Cytostatica and small intestine (author's transl)].
Cytostatica not only suppress proliferation in tumor cells but it also checks proliferation in small intestinal epithelium. The consequence is cell reduction and damage resulting in a diminished function. Because of the high reserve capacity of the small intestinal epithelium, clinical signs of diminished function are mostly seen after repeated high doses or one extremely high doses of Cytostatica. Although there is abundant information on the effect of Cytostatica on the small intestinal epithelium (cell turnover, morphology, digestive enzymes and absorption) there are other areas that are as urgent for the interested clinician to work on: 1. Would it be possible to coincide the dose and dosage rate with the cell cycles to reduce the chance of damage to small intestinal epithelium? 2. Which role has the luminal content when there is damage from Cytostatica? Is it possible to concentrate on changing the luminal contents (antibiotics, "elemental diet", cultivate desirable microflora, etc.) Therefore diminishing the damage from Cytostatica? 3. How would Cytostatica influence the barrier function on the intestinal wall? Should the patient on Cytostatica therapy receive special protection against intestinal infection? 4. Does Cytostatica affect the biotransformation in the small intestinal epithelium, especially when taken orally? How important is this biotransformation in small intestinal epithelium damaged by Cytostatica therapy? 5. What factors determine the regeneration of the small intestinal epithelium after Cytostatica damage?